American Century Companies Inc. Raises Position in Denali Therapeutics Inc. (NASDAQ:DNLI)

American Century Companies Inc. increased its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 6.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 480,529 shares of the company’s stock after buying an additional 29,155 shares during the quarter. American Century Companies Inc. owned 0.33% of Denali Therapeutics worth $9,793,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in DNLI. PNC Financial Services Group Inc. grew its position in Denali Therapeutics by 30.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company’s stock worth $77,000 after purchasing an additional 885 shares during the period. KBC Group NV boosted its stake in shares of Denali Therapeutics by 75.8% in the fourth quarter. KBC Group NV now owns 6,334 shares of the company’s stock worth $129,000 after buying an additional 2,731 shares during the last quarter. AlphaQuest LLC grew its holdings in Denali Therapeutics by 177.1% during the fourth quarter. AlphaQuest LLC now owns 6,961 shares of the company’s stock worth $142,000 after acquiring an additional 4,449 shares during the period. E Fund Management Co. Ltd. raised its position in Denali Therapeutics by 32.2% during the fourth quarter. E Fund Management Co. Ltd. now owns 9,997 shares of the company’s stock valued at $204,000 after acquiring an additional 2,436 shares in the last quarter. Finally, SG Americas Securities LLC lifted its holdings in Denali Therapeutics by 128.8% in the fourth quarter. SG Americas Securities LLC now owns 11,003 shares of the company’s stock valued at $224,000 after acquiring an additional 6,195 shares during the period. 92.92% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, insider Carole Ho sold 12,255 shares of the company’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $20.22, for a total transaction of $247,796.10. Following the transaction, the insider now owns 178,580 shares of the company’s stock, valued at $3,610,887.60. This represents a 6.42 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Steve E. Krognes sold 3,339 shares of the company’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $20.81, for a total transaction of $69,484.59. Following the sale, the director now owns 25,757 shares of the company’s stock, valued at $536,003.17. The trade was a 11.48 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 44,860 shares of company stock valued at $909,039 over the last three months. 7.90% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on DNLI shares. Baird R W raised shares of Denali Therapeutics to a “strong-buy” rating in a report on Tuesday, January 7th. Stifel Nicolaus upgraded Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 price target for the company in a research note on Monday, December 16th. Robert W. Baird started coverage on Denali Therapeutics in a research report on Tuesday, January 7th. They set an “outperform” rating and a $31.00 price target on the stock. JPMorgan Chase & Co. cut their price objective on Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating for the company in a research report on Tuesday, January 7th. Finally, The Goldman Sachs Group decreased their target price on Denali Therapeutics from $45.00 to $40.00 and set a “buy” rating on the stock in a research report on Tuesday, January 28th. Two analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Denali Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $37.20.

Denali Therapeutics Stock Performance

Shares of DNLI opened at $13.74 on Thursday. Denali Therapeutics Inc. has a 52 week low of $12.05 and a 52 week high of $33.33. The company’s 50 day moving average price is $18.48 and its 200 day moving average price is $22.91. The company has a market capitalization of $2.00 billion, a PE ratio of -4.98 and a beta of 1.58.

Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Thursday, February 27th. The company reported ($0.67) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.08. On average, equities analysts forecast that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.